Bronchiectasis – Pipeline Review, Q1 2011
Bronchiectasis - Pipeline Review, Q1 2011
Reference Code: GMDHC202IDB
Publication Date: March 2011
Bronchiectasis – Pipeline Review, Q1 2011 GMDHC202IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Page(1)
Bronchiectasis – Pipeline Review, Q1 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchiectasis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bronchiectasis 7
Bronchiectasis Therapeutics under Development by Companies 9
Bronchiectasis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Bronchiectasis Therapeutics - Products under Development by Companies 16
Bronchiectasis Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Bronchiectasis Therapeutics Development 18
Aradigm Corporation 18
Gilead Sciences, Inc. 18
Discovery Laboratories, Inc. 19
Bayer AG 19
Pharmaxis Ltd. 20
RegeneRx Biopharmaceuticals, Inc. 20
Aridis Pharmaceuticals LLC 21
NexBio, Inc. 21
Bronchiectasis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Late Stage Drug Profiles – Companies 28
Bronchitol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Late Stage Drug Profiles – Universities/Institutes 29
Azithromycin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Bronchiectasis - Featured News 31
Oct 20, 2010: Aradigm Reports Successful Phase IIb Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin 31
Bronchiectasis – Pipeline Review, Q1 2011 GMDHC202IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Bronchiectasis – Pipeline Review, Q1 2011
Sep 17, 2010: Aradigm Presents Results Of ARD-3100 For Treatment Of Bronchiectasis At 2010 European Respiratory Society Annual
Congress 32
Sep 17, 2010: Aradigm Presents Results Of ARD-3150 For Treatment Of Bronchiectasis At 2010 European Respiratory Society Annual
Congress 32
Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis 33
Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT 33
Jan 16, 2007: Aradigm Receives FDA Orphan Drug Designation For Liposomal Ciprofloxacin For Bronchiectasis 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 36
Contact Us 36
Disclaimer 36
Lis t o f Ta b le s
Number of Products Under Development for Bronchiectasis, Q1 2011 7
Products under Development for Bronchiectasis – Comparative Analysis, Q1 2011 8
Comparative Analysis by Late Stage Development, Q1 2011 12
Comparative Analysis by Mid Clini